Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating E/C/F/TAF fixed-dose combination in HIV-1 infected adults on chronic hemodialysis completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• E/C/F/TAF (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-10-16